



# PRECISEU

## WORK PACKAGE 1

### D 1.4 Year 2 Annual Work Plan

Biocat

05/07/2025

## DISCLAIMER

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.



**Co-funded by  
the European Union**

# TABLE OF CONTENTS

CONSORTIUM PARTNERS.....	5
WORK PACKAGES AND LEADERS.....	6
LIST OF ACRONYMS .....	7
1. ABOUT THIS DELIVERABLE.....	9
1.1 METHODOLOGY.....	9
1.2 VERIFICATION OF Y1 AWP OBJECTIVES ACHIEVEMENT .....	10
2. YEAR 2 AWP OBJECTIVES .....	12
2.1 CORRESPONDANCE WITH PART B OF THE PROPOSAL .....	12
2.2 EXPECTED OUTCOMES AND IMPACT .....	14
3. ANNUAL WORK PLAN ACTIVITIES .....	17
3.1 STRUCTURE OF THE ANNUAL WORK PLAN.....	17
3.2 CALENDAR OF TASKS, PROGRAMMED ACTIVITIES AND DELIVERABLES.....	18
3.3 DETAILED WORK DESCRIPTION .....	23
3.4 PARTNERS' PARTICIPATION IN ANNUAL WORK PLAN ACTIVITIES.....	45
3.5 RESOURCES TO BE COMMITTED.....	49

Project information	
Project title	PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope
Acronym	PRECISEU
Project URL	<a href="https://cordis.europa.eu/project/id/101161301">https://cordis.europa.eu/project/id/101161301</a>
Grant Agreement n.	101161301
Call	<a href="#">HORIZON-EIE-2023-CONNECT-03</a>
Call Topic	HORIZON-EIE-2023-CONNECT-03-01- Implementing co-funded action plans for connected regional innovation valleys
Type of Action	<a href="#">HORIZON-COFUND- HORIZON Programme Cofund Actions</a>
Project start/end date	01/07/2024-30/06/2029
Project duration	60 months
EU Project officer	Christina Nanou (EISMEA)
Project coordinator	Montse Daban (Biocat)
Project manager	María Cejas (Biocat)

Deliverable information	
Deliverable n.	1.4
Work package n.	WP1. Project Management and Coordination
Deliverable title	Annual Work Plan Year 2
Lead beneficiary	Biocat
Participants	All partners
Main authors	María Cejas (Biocat)
Contributors	Montse Daban (Biocat) and All Partners
Reviewed by	Montse Daban (Biocat) and All Partners
E-mail Contact for queries	<a href="mailto:mcej@biocat.cat">mcej@biocat.cat</a>
(Requested delayed) Submission date	06/07/2025
Due date	30/06/2025
Document status	Final
Document version number	1
Document type*	R (REPORT)
Dissemination level	Public

# CONSORTIUM PARTNERS

	Name of the Entity	Acronym	Role	Country
1	Biocat LA FUNDACIO BIOREGIO DE CATALUNYA	Biocat	COO	ES
2	DEPARTAMENT DE SALUT- GENERALITAT DE CATALUNYA	SALUT	BEN	ES
3	BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION	BSC-CNS	BEN	ES
4	BIORN CLUSTER MANAGEMENT GMBH	BIORN	BEN	DE
5	BIOPRO BADEN-WUERTTEMBERG GMBH	BIOPRO	BEN	DE
6	AGENTIA PENTRU DEZVOLTARE REGIONALA NORD-EST	NE RDA	BEN	RO
7	ASOCIATIA DIGITAL INNOVATION ZONE ZONA DE INOVARE DIGITALA	DIZNE	BEN	RO
8	CLUSTERUL REGIONAL INOVATIV DE IMAGISTICA MOLECULARA SI STRUCTURALA NORD-EST (IMAGO-MOL)	IMAGO-MOL	BEN	RO
9	BIOTEHNOLOGICHEN I ZDRAVEN KLASTER	HLSCB	BEN	BG
10	STOLICHNA OBSHTINSKA AGENTSIA ZA PRIVATIZATSIA I INVESTITSII	SIA	BEN	BG
11	CLUSTER INDUSTRIE DELLA SALUTE E DEL BENESSERE	CLUST-ER HEALTH	BEN	IT
12	REGIONE EMILIA ROMAGNA	RER	BEN	IT
13	ART-ER-SOCIETA CONSORTILE PER AZIONI	ART-ER	BEN	IT
14	VLAAMSE GEWEST	EWI	BEN	BE
15	MEDVIA	MEDVIA	BEN	BE
16	VIESOJI ISTAIGA INOVACIJU AGENTURA	IA LITHUANIA	BEN	LT
17	BRG, BUSINESS REGION GOTEBOG AB	BRG	BEN	SE
18	EATRIS ERIC	EATRIS	BEN	NL
19	PLATAFORMA DE ORGANIZACIONES DE PACIENTES	POP	BEN	ES
20	AGENCIA PER A LA COMPETITIVITAT DE LA EMPRESA	ACCIO	BEN	ES
21	IDRYMA TECHNOLOGIAS KAI EREVNAS	FORTH-ICS	BEN	EL
22	REGION OF CRETE	KRITI	BEN	EL
23	SAHLGRENSKA SCIENCE PARK AB	SSP	BEN	SE
24	RIVNE INTERREGIONAL MEDICAL CLUSTER	RIVNE	BEN	UA
25	ASTRAZENECA FARMACEUTICA SPAIN S.A.	ASTRA ZENECA	BEN	ES

# WORK PACKAGES AND LEADERS

Work Packages Name		WP Leader
WP 1	Project Management and Coordination	Biocat
WP 2	Communication and Dissemination	NE RDA
WP 3	Interregional Collaboration and Partnership Bridging	IA Lithuania
WP 4	Use of Health Data	ART-ER
WP 5	Multistakeholder infrastructure to enable access to ATMP on large scale	BIO PRO
WP 6	Market and Patient Access	SSP
WP 7	Training and Cultural Change	HLSCB
WP 8	Adoption of PM innovations in the HealthCare System	SALUT
WP 9	Innovation Support Program	Biocat

## Intellectual Property Rights (IPR)

This deliverable is an open access report, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, if you give appropriate credit to the original author(s). The contributing partners own right on their contents, following the project grant agreement (1011621301).

## How to quote this document

Cejas, Maria, et al., (2025). PRECISEU D1.4 Annual Work Plan Year 2. Biocat.<sup>1</sup>

---

<sup>1</sup> The co-authors of this AWP are all the PRECISEU consortium members.

# LIST OF ACRONYMS

Acronym	Meaning
AB	Advisory Board
ACT	Activity
ATMPs	Advanced Therapy Medicinal Products
AWP	Annual Work Plan
BEN	Beneficiary
CON	Connection and synergies meeting/visit
CT	Coordination Team
CY	Cyprus
D#.##	Deliverable (as in D1.4 = deliverable 1.4)
DK	Denmark
DMP	Data Management Plan
DoA	Description of Action
EHDS	European Health Data Space
EISMEA	European Innovation Council and SMEs Executive Agency
EOI / EoI	Expression of Interest
EP PerMed	European Partnership for Personalised Medicine
FAIR	Findability, Accessibility, Interoperability, and Reusability
FSTP	Financial Support to Third Parties
FU	Funneling
GA	Grant Agreement
GAM	General Assembly Meeting
GEDI	Gender Equality Diversity and Inclusion
IC Permed	International Consortium on Personalised Medicine
IR	Internal Report
ISP	Innovation Support Programme
JIP	Joint Interregional Project
KoM	Kick-Off Meeting
KPI	Key Performance Indicator
M#	Month (as in M13 = month 13 of the project)
MGM	Maturity Grid Model
Ms	Milestone
NEIA	New European Innovation Agenda
PM	Personalised Medicine
PMS	Personalised Medicine School
RIS3	Regional Smart Specialisation Strategy
RIVs	Regional Innovation Valleys
RP	Reporting Period


SC	Steering Committee
SG	Strategic Group
SKG	Stakeholders Group
SMEs	Small and Medium Enterprises
SRIA	Strategic Research and Innovation Agenda
ToA	Triplets of Action (referred to IC PerMed's SRIA on Personalised Medicine)
T#.#	Task (as in T9.2 = task 9.2)
WP	Work Package

# 1. ABOUT THIS DELIVERABLE

Deliverable 1.4 is dedicated to the year 2 Annual Work Plan. It builds on impact realisation and innovation support mechanisms. As the project transitions from initial structuring and implementation to full-scale deployment, Y2 AWP acts as a critical bridge between the foundational efforts of Year 1 and the operationalisation of interregional collaboration, capacity-building, impact realisation and innovation support mechanisms.


## 1.1 METHODOLOGY

PRECISEU Coordination Team has drafted in parallel a 12 month Progress Report and the Year 2 Annual Work Plan, with the contribution of all WP leads and the collaboration of all PRECISEU partners.



**Figure 1.** The internal progress report and the Y2AWP have been drafted in parallel by the Coordination Team (CT) and the Work Package Leads (WPL) during M11 and 12 of the project.

For the detailed tasks of the process Y2 AWP preparation, please refer to Figure 2. The process has been implemented in parallel to the M12 Internal Progress Report, to ensure alignment and to facilitate revision of KPIs. As indicated in the Grant Agreement, Work Plans shall be adjusted as required to mitigate risks and ensure proper tracking and achievement of the established indicators.



**Figure 2.** As agreed in the Project Handbook, the process of Y2AWP drafting has been treated as a deliverable, with cross- review and submission to Funding and Tenders Portal, with writing and reviewing periods approved by all partners.

Guided by the overarching ambition to accelerate the adoption of Personalised Medicine (PM) across Europe through connected regional ecosystems, Y2 AWP reflects the project’s strong commitment to address fragmentation, strategic alignment, scaling up deep-tech healthcare innovations, in full coherence with the strategic roadmap and the Monitoring and Evaluation Framework displayed in in Part B, Impact section, of the Grant Agreement. For this reason, the consortium has performed a consistent cross-check for alignment of project activities and methodology with the GA and with the strategy agreed, in particular with IC PerMed’s SRIA ToAs.

## 1.2 VERIFICATION OF Y1 AWP OBJECTIVES ACHIEVEMENT

The consortium has also verified that the previous AWP (Year 1) reached the expected outcomes. The Consortium will implement in Y2 specific actions aimed to mitigating risks and deviations impact upon discussion in the planned GAM in M 15.

**Table 1.** Y1 AWP Objectives, achievement level and means of verification.

#	Objective	Status	Achievement verification
1	Settling the governance of the PRECISEU consortium and establishing the core procedures for working in the project.	Achieved	Deliverables D1.1, Milestone 1, Internal Progress Report (IPR) M6 and M12 (available to EISMEA)
2	Developing within the Steering Committee exit and phasing out strategies to ensure that PRECISEU has a sustainability strategy that is coherent with resource availability and individual organisational strategies.	Ongoing (to be developed during all project)	Steering Committee Minutes, IPR M6 and M12 (available to EISMEA), WP3 outcomes, list of attended activities
3	Creating a sound project brand by generating the PRECISEU's communication toolkit, launching its public platform and starting dissemination actions both online and in events or other onsite settings.	Achieved	Deliverables D2.1 to D2.4. IPR M6 and M12 (available to EISMEA). Launching of Website, Insights and newsletters. Achievement of label, PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website
4	Leading by example the ELSI considerations in PM, by planning and performing a GEDI assessment within the PRECISEU project, and transferring the learnings through publication of the results.	Ongoing (to be consolidated in Y2 AWP)	Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website
5	Mapping update of the PM in the participating regions (policies, infrastructures, hurdles strengths, etc.). Such mapping exercise will be focused on the use of health data and the development of ATMPs, and how current market rules and industrial landscape frame these PM aspects.	Achieved and to be updated during the project	Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website
6	Developing the first set of guidelines over the base of the mapping to initiate the innovation support programme in the 2nd year of PRECISEU	Achieved	D9.1, Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website
7	Fostering the co-creation of solutions that bring an advance to the implementation of PM through a hackathon constructed over the first results of WP4, WP5 and WP6	Achieved	Hackathon in Gothenburg and Barcelona (Feb 2025), Grand Finale (Gothenburg Oct 25), Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website
8	Identifying the involvement of the regional stakeholders of each ecosystem in the main EU-wide initiatives and networks and establishing the first connection between PRECISEU and the most relevant initiatives, as part of the engagement and advocacy activities.	Achieved	T3.2, Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website
9	Increasing the visibility of best practices in the PM area by organising and hosting the first edition of the PRECISEU best practices awards	Achieved, to be delivered M15	Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website.
10	Preparing the contents and structure for talent development through the first PM school and the policymaker Biodesign programme, that will be launched at year 2.	Achieved, to be delivered M16-17	Internal Progress Report (IPR) M6 and M12 (available to EISMEA), PRECISEU Insights and Newsletters, PRECISEU LinkedIn and Website

It becomes clear from the table above the relevance to continue consolidating Y1 achieved objectives and implementing actions to realise goals under ongoing or not completed status of achievement.

## 2. YEAR 2 AWP OBJECTIVES

The general objective of the Year 2 Annual Work Plan (covering M13–M24) is to **consolidate the deployment of PRECISEU**, building on the governance structures, analytical groundwork and strategic alignments established during Year 1.

Specifically, the Y2 AWP aims to:

- **Accelerate the operationalisation of key pillars of the project**, including the launch of the Innovation Support Programme (in WP9), the deployment of interregional collaboration actions (in WP3), and the advancement of data and infrastructure frameworks (in WPs 4 and 5).
- **Ensure coherence, complementarity and progress across all Work Packages**, supporting the achievement of expected outcomes, of project milestones and of KPIs, through coordinated monitoring, reporting, and governance.
- **Enhance integration and visibility of regional strategies and ecosystems**, fostering a collaborative environment for the co-development and scaling of personalised medicine (PM) solutions across Europe.
- **Initiate cross-regional activities and joint initiatives** that directly contribute to the objectives defined in the Strategic Agenda (SRIA) of EP PerMed and the European Innovation Ecosystems under the New European Innovation Agenda (NEIA).

The implementation of Year 2 of PRECISEU maintains its strong alignment with the strategic vision outlined in Part B of the Grant Agreement, particularly in its commitment to:

- Reducing fragmentation in personalised medicine innovation across Europe,
- Supporting the development and adoption of deep-tech solutions in healthcare, and
- Enabling sustainable interregional collaboration through co-funded, mission-driven actions.

### 2.1 CORRESPONDANCE WITH PART B OF THE PROPOSAL

PRECISEU's Year 2 Annual Work Plan (Y2 AWP) (M13–M24) builds directly on the strategic vision, general and specific objectives outlined in Part B of the Grant Agreement, covering its general, specific, and operational objectives..

Year 2 must unlock all lagging aspects of interregional collaboration relevant to PRECISEU success. The launch of the Innovation Support Programme is a crucial milestone, both designed to align regional and EU strategies and to facilitate the advancement of innovation in healthcare. A relevant aspect of Y2 will be overcoming the multiple barriers encountered to implement the FSTP. Namely

- Commitment of funding from Regions
- Mechanism and structure of the funding
- Correct implementation from the regions, according to their particularities
- Collaboration with EISMEA and the EC in the proper implementation of the funding

Support frameworks and training actions directly respond to the project's **General Objective (GO)** of increasing the efficiency of regional innovation ecosystems by leveraging shared resources and specialisations to accelerate the adoption of personalised medicine in Europe.

More specifically, the Year 2 activities contribute to the following **Specific Objectives (SOs)** outlined in Part B:

- **SO1:** Interconnecting diverse European innovation ecosystems via WP3 and WP9 coordination efforts, enabling collaboration between high-performing and emerging regions.
- **SO2:** Aligning regional strategies with the EP PerMed SRIA and RIS3, through joint planning processes and cross-regional actions.
- **SO3:** Developing frameworks and tools (WP4, WP5) to support sustainable and equitable integration of PM into healthcare systems.
- **SO4:** Fostering innovation alliances and business models along PM value chains via WP6, WP8 and the future implementation of JIPs.
- **SO5:** Empowering regional actors through training initiatives such as the PRECISEU Summer School and Digital Training Programme (WP7).
- **SO6:** Operationalising the Innovation Support Programme through mentoring, funnelling and launching the Open Call for interregional projects (WP9).

Additionally, the Y2 AWP corresponds directly with the **Operational Objectives** that structure the PRECISEU work plan, especially by:

- Supporting the deployment and scalability of **innovative PM solutions**, particularly those at **TRL6–8**, through coordinated co-investment and targeted capacity-building.
- Advancing toward the **integration of health data and ATMPs** into regional strategies and infrastructures, enabling clinical translation and interoperability.

- Strengthening regional preparedness and resilience by integrating Ukraine's **Rivne Medical Cluster** into European innovation networks, offering a unique opportunity to contribute to post-crisis health system reconstruction and digital health leadership.
- Enhancing synergies with EU-level priorities on **resilience, strategic autonomy and the twin green and digital transitions**, as defined under the **New European Innovation Agenda** and **Horizon Europe's** expected outcomes.

All these efforts are framed by a **SMART (Specific, Measurable, Achievable, Relevant and Time-bound)** logic, with key deliverables and milestones defined for the reporting period. The Year 2 AWP is therefore not only consistent with the original strategic framework of the project, but it also marks the first major step in translating PRECISEU's ambitions into **operational impact on the ground**.

## 2.2 EXPECTED OUTCOMES AND IMPACT

During Year 2, PRECISEU will transition from its initial phase, which had its focus on launching the project, setting up governance structure and strategic groundwork, elaborating shared materials and creating awareness on the project, to a second year with a focus on the active implementation of key actions, build consistency across Work Packages and pilot impactful actions. The activities planned for this period are expected to generate tangible and strategic impacts at both regional and European levels. The main expected outcomes and their related impacts include:

1. **Enhanced interregional collaboration**, through the launch of the Innovation Support Program (ISP) and the funding of JIPs at the end of the year, PRECISEU will enable cross-border cooperation and shared innovation efforts in personalised medicine.

### IMPACT:

- The projects funding will help align regional and EU policies in the long run
- The pilots will lay the grounds for PRECISEU long term exploitation and sustainability plan. According to the GA, this period will allow for the identification of country / regional partners that will continue PRECISEU.

2. **Mobilisation of innovation ecosystems**, by engaging SMEs, research and healthcare institutions, and public agencies in co-funded, mission-driven initiatives that address priority challenges in the use of health data and access to advanced therapies.

### IMPACT:

- PRECISEU calls will ignite interregional pilots and collaborative developments advancing innovation from TRL 6 to 8 on Health Data and ATMPs

- European hubs with different innovation levels prioritise healthcare and PM in their strategies, inclusively representing diverse stakeholders.
3. **Stronger positioning of PRECISEU as a flagship initiative within the Regional Innovation Valleys (RIV) framework**, showcasing how cross-regional coordination, aligned funding mechanisms and stakeholder engagement can operationalise the ambitions of the NEIA and the EP PerMed SRIA. PRECISEU will continue to contribute to shaping the vision of interconnected health innovation ecosystems, as a reference initiative within the EU innovation landscape, participating in strategic positioning events.

**IMPACT:**

- PRECISEU becomes a well-known brand for a dynamic initiative to promote PM across Europe, with experts and top events and activities.
  - PRECISEU raises awareness on PM implementation good practices and models.
  - PRECISEU is recognised as a good practice itself across EU among RIVs and supports the EC in decision making processes regarding the subject of interest.
  - Increased solutions aligned to IC PerMed SRIA's ToAs.
  - Positive perception of Regional authorities on the support that PRECISEU has generated to address PM obstacles.
4. **Advance towards a multistakeholder infrastructure of ATMPs across Europe**  
Year 2 will advance towards a multistakeholder ATMP development infrastructure defined including governance and access model, plus service catalogue.

**IMPACT:**

- Cooperation pilots might be established between hospitals and research/industry upon implementation of multistakeholder infrastructure
  - ATMPs can be developed through the multistakeholder infrastructure and collaboration models.
5. **Progress towards interoperability and infrastructure readiness**, through the development of governance models, reference frameworks, and service catalogues related to data use and ATMPs, setting the stage for long-term adoption.

**IMPACT:**

- Increased knowledge on EHDS readiness across Europe and on good practices at regional and national level.
- PRECISEU outcomes support policymakers in the decision making process to implement or improve the building blocks at regional or national level

- PRECISEU ignites reflections and discussions involving all stakeholders, thus contributing to increase the awareness on the relevance of accelerating EHDS implementation
  - PRECISEU helps, by emerging and finding projects and developments on Health Data interoperability, to accelerate the process of secondary use data sharing.
6. **Boosting education and capacity-building in personalised medicine**, through the launch of the first PRECISEU Summer Schools and the pilot of the Design Thinking for Policy makers (DTPM). These initiatives aim to equip professionals across the quadruple helix with the skills and knowledge required to implement PM solutions in diverse regional contexts.

**IMPACT:**

- Training 2 cohorts of professionals on Personalised Medicine with focus on Health Data and AI (Y2), PRECISEU builds talent to be deployed in the ecosystems of Rumania and Sweden as well as across EU.
  - Increased awareness on barriers to innovation and the need to flexible, yet caution, interpretations of regulation around PM
  - Cohorts of policymakers with increased contact with innovators and a better understanding of the innovation process ad its impact on society
7. **Stronger internal coordination and knowledge sharing**, via continuous project monitoring, cross-WP review processes, and integration of feedback from the Advisory Board.


**IMPACT:**

- PRECISEU implementation is efficient and helps transform the participating regions and their innovation ecosystems, increasing on the long run the competitiveness of the EU
- Increased participation of Ukraine in EU projects and preparation for the SMP entry

Together, these outcomes and impacts will help **reduce fragmentation, promote regional cohesion, and accelerate the uptake of PM innovations** across Europe.

# 3. ANNUAL WORK PLAN ACTIVITIES

## 3.1 STRUCTURE OF THE ANNUAL WORK PLAN



**Figure 3.** PRECISEU implementation process is divided into 9 Work Packages: 3 transversal ones (management, communication and networking and engagement); 4 content-generating WPs (Health Data, ATMPs, Market and Health Systems implementation) 1 capacity-building WP and 1 WP devoted to launching and managing the FSTP calls.

PRECISEU’s AWP for the second year of the project is structured including 31 different active tasks (of the 35 total distributed in 9 WPs).

In general terms, the bulk of these tasks are either continuous across the whole project, or preparatory of actions that will take place in the following 4 years. Some other tasks in this second period are only expected to be kicked off. The different tasks explained in the Part B of the project proposal and in the Grant Agreement have several activities linked, which are also detailed in this report, including the resources allocated to them.

### 3.2 CALENDAR OF TASKS, PROGRAMMED ACTIVITIES AND DELIVERABLES

WP	TASK	PARTNER S INVOLVE D	2025						2026						
			JUL	AGO	SEPT	OCT	NOV	DEC	JAN	FEB	MAR	APR	MAY	JUN	
WP 1: Project Management and Coordination	T 1.1 Project Management and Governance (M1-M60)	Biocat GA, KOM , CA	SC	No SC	GAM Onsite Vilnius	SC+ AB	SC	SC	SC	GAM online	SC + AB	SC	SC	GAM Onsite Sofia	
	T 1.2 Project monitoring, reporting and quality assurance (M1-M60)		PRECISEU Insights	PRECISEU Insights	PRECISEU Insights	PRECISEU Insights 2 <sup>nd</sup> Financial Webinar	PRECISEU Insights	PRECISEU Insights 18 M PR	PRECISEU Insights	PRECISEU Insights	PRECISEU Insights	PRECISEU Insights	PRECISEU Insights	PRECISEU Insights	D1.9 IPR PRECISEU Insights
	T 1.3 Annual Work Programs and Project Sustainability (M10-M60)		Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	Activity and financial tracking	D1.5 Activity& financial tracking
WP 2: Communication and dissemination	T 2.1 Development and implementing the Communication Plan	NERDA	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	STRATEGY REVIEW	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	CAMPAIGN FOCUS IN PARTNER	
	T 2.2 Creation of the communication and dissemination toolkit	NERDA			REVIEW& UPDATE					REVIEW& UPDATE					

	T 2.3 E3 Promotion of the PRECISEU project activities	NERDA	EOIs	Awards	QUARTERLY NEWSLETTER and Hackathon	EU Presidency and DTPM	PRECISEU School and calls ATMP Campaign	QUARTERLY NEWSLETTER and 18 month progress	Projects awarded	Projects start	QUARTERLY NEWSLETTER	EU Presidency	QUARTERLY NEWSLETTER
	T2.4 Setting up, Launching and curating the PRECISEU website	Biocat	B2Match for Eols			Phase 2			Phase 3				Update
<b>WP3: Connecting, complementing and bridging</b>	T3.1 Partner regions landscape	IA LIT				D3.1							
	T3.2 Connect and complement main international PM driving initiatives	Biovia	Update and enlarge			CONNECT TEHDAS2			CONNECT VISIT UK				
	T 3.3 Multistakeholder Alignment	BRG				AB CONSULTATION							AB CONSULTATION
	T3.4 Scaling up the dialog on ATMPs / PM at policymaking related fields	Biocat			D3.4 DK Case Study	EU Presidency DK				D3.5 Cyprus Case Study		EU Presidency CY	
	T 3.5 Ethical, Legal and Societal Implications (ELSI)	EATRIS			Guideline Draft 1				Guideline				
<b>WP4: EUse of Health-related Data</b>	T 4.1 Assessing Readiness to EHDS	BIOPRO			D4.1 EHDS report								
	T 4.2 Requirements and tools for data storage and data	BSC	INTERVIEW SERIES			INTERVIEW SERIES							

	processing in the EHDS													
	T 4.3 Technical, Syntactic, and Semantic Interoperability: from standards to FAIR by design approaches	BSC												D4.2 interoperability framework
	T 4.4 Guidelines for the activation of Joint Interregional Projects in Personalised Medicine	BSC				1 <sup>st</sup> DRAFT JIPs DMP								
	T 5.2 Multistakeholders' Infrastructure for development, production, and use/implementation of ATMPs	EATRIS			Launch ATMP Map at ATE 25 Barcelona	ATMPs at Biospain				Update ATMP Map				D5.2 D5,4 ATMPs at BIO US
	T 5.3 Enable access and growth of the open infrastructure for ATMPs	BIORN												D5.3
	T 5.4 Facilitate patients access to ATMPs	BIOPRO					C&G Therapy Intl Berlin	AT Week San Diego	CAR-TCR Summit Europe , UK	AT London	C&G Therapy on the Med	ISCT Dublin		BIO San Diego

WP 6 Market and Patient Access	T 6.1 Mapping and nailing main restraints for implementation of Precision care in each region	SSP			D6.1									
	T 6.2 Develop model and roadmap for best implementation of Precision care	SSP				Summary Brief for DK event HACKATHON FINALE	Mapping at PM School		Roadmap drafting		Open Collaboration Model		Summary Brief for CY event	PM roadmap
WP7: Capacity Building and Cultural Change	T7.1 Repository for capacity building	HLSCB	D7.1			Launch Platform Repository			Update and Expand repository					
	T7.2 Best regional practices recognitions	BIORN	D7.2		Edition 1 Awards						Launch Y2 Awards			
	T7.3 Training Program	DIZNE	1 <sup>st</sup> PM School				2 <sup>nd</sup> PM School							
	T7.4 Transforming policymaking	Biocat	D7.3				Pilot DTPM Training							
WP8: Sustainable and affordable introduction of PM into healthcare	T 8.1 Reimbursement and procurement models for PM	SALUT						D8.1						
	T8.2 PM pathways in the clinical practice	SALUT						D8.2						
	T8.3 Maturity assessment of PM innovations towards value-based adoption in	SALUT						D8.3						

	the healthcare system													
	T 9.2 Topic and participant funnelling action	ACCIO	Eols close	FUNNE PROCESS	FUNNE PROCESS	FUNNE PROCESS								
	T 9.3 FSTP administrative and financial processes	Biocat					CALLS LAUNCH	CALLS LAUNCH	EVALUATION AND GA	Projects start				
	T 9.4 Project monitoring quality and outcome assessment	ACCIO												

**Note: Only tasks with activities programmed in Y2 appear in the table.**

**Legend of acronyms used in the Calendar of Activities:**

ACT – Activity

CON- Connection and synergies meeting/visit

CY- Cyprus

DK – Denmark

FU- Funnelling

IR – Internal Report

PMS – Personalised Medicine School

R – Recognitions

RP – Reporting Period

SG – Strategic Group

SKG – Stakeholders Group

### 3.3 DETAILED WORK DESCRIPTION

Table 2.3.a: Annual Work Plan Activities for each set of activities<sup>2</sup>:

#### FOR WP1- BIOCAT

Set of Activities Number	WP1	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Project Management & Coordination			
Participant number & acronym	1- Biocat	2 – SALUT	3- BSC	4- BIORN
Person-months per Participant	12	0.36	0.1	0.1
Participant number & acronym	5 – BIOPRO	6– NE RDA	7 – DIZNE	8 – IMAGO-MOL
Person-months per Participant	0.36	0.36	0.1	0.1
Participant number & acronym	9 – HLSCB	10- SIA	11 – CLUST-ER	12- RER
Person-months per Participant	0.36	0.1	0.1	0,1
Participant number & acronym	13 – ART-ER	14- EWI	15- Biovia	16 – IA Lithuania
Person-months per Participant	0,36	0,1	0,2	0,36
Participant number & acronym	17- BRG	18- EATRIS	19- POP	20- ACCIÓ
Person-months per Participant	0,1	0,2	0,1	0,2
Participant number & acronym	21 – FORTH-ICS	22- KRITI	23- SSP	24- RIMC
Person-months per Participant	0,1	0,1	0,36	0,08
Participant number & acronym	25- ASTRAZENECA			
Person-months per Participant	0,1			
Start month	M13: July 2025	End month	M24: June 2026	
Objectives:				

<sup>2</sup> In this section tables numbered according to Grant Agreement to facilitate comparison.

1. **Ensure effective coordination and governance continuity**  
Maintain the operation of project bodies (CT, GA, SC, AB), facilitate regular Steering Committees, and integrate Advisory Board feedback into project strategy.
2. **Support implementation, monitoring and reporting**  
Track WP progress, milestones and KPIs; provide quality control of deliverables; and guide partners in preparation for the first EU reporting period (RP1) in M18.
3. **Foster internal communication and strategic planning**  
Strengthen partner engagement through SharePoint and PRECISEU Insights and coordinate the preparation and submission of the Annual Work Plan Y3 (D1.5)

#### **Description of Programmed Activities:**

*Related to tasks (activities described in bullet points)*

##### **T1.1 Project Management and Governance (M13-M24)**- Partners involved: Biocat (Lead), WP leads

- Organise and facilitate monthly Steering Committee meetings, continuing the WP-focused approach launched in Y1.
- Prepare and support the organization of the General Assembly Meetings (GAM)
  - Onsite, Vilnius, Lithuania, aligned with the Life Sciences Baltics event (M15)
  - Online (M20)
  - Onsite, Sofia, Bulgaria, ensuring alignment with the Spin-off Bulgaria (M24)
- Coordinate Advisory Board interactions, including participation in key project milestones and feedback on strategic deliverables.
- Maintain and update governance-related documentation and templates.
- Support efficient coordination between WPs and ensure smooth internal workflows across the consortium.

##### **T1.2 Project monitoring, reporting, and quality assurance (M13-M24)**- Partners involved: Biocat (Lead), WP leads

- Monitor WP-level progress against KPIs, milestones and deliverables, and ensure timely internal follow-up.
- Implement internal review and quality assurance protocols for deliverables due in Y2.
- Support partners in the preparation for **Periodic Reporting 1 (RP1)**, including guidance on financial and technical reporting obligations with the organization of a Financial Webinar.
- Organise a second **Financial Reporting Webinar** to address remaining questions ahead of RP1.
- Track risk mitigation actions and maintain the risk register updated throughout the year.
- Consolidate inputs and validate content for internal documents (e.g. internal progress updates, WP dashboards, etc.).

##### **T1.3 Annual Work Programs and Project Sustainability (M13-M24)** - Partners involved: Biocat (Lead), WP leads

- Coordinate the preparation, review, and submission of the **Annual Work Plan for Year 3 (D1.5)**, including partner consultations and cross-WP alignment at M24.

- Facilitate an internal cross-WP review process for AWP drafts to ensure coherence, avoid overlaps, and identify synergies.
- Begin integrating sustainability-related elements into strategic planning discussions, particularly in connection with WP4 and WP5.
- Monitor the implementation of Y2 AWP and align ongoing activities with longer-term project objectives.

**Additional Deliverables** (if applicable- brief description and month of delivery)

*Not applicable.*

## FOR WP2 – NE RDA

Set of Activities Number	WP2	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Communication and Dissemination			
Participant number & acronym	1 – Biocat	2 – SALUT	3- BSC	4- BIORN
Person-months per Participant	5 <sup>3</sup>	0,2	0.1	0.4
Participant number & acronym	5 – BIOPRO	6– NE RDA	7 – DIZNE	8 – IMAGO-MOL
Person-months per Participant	0.6	6,4 <sup>4</sup>	0.4	0.6
Participant number & acronym	9 – HLSCB	10- SIA	11 – CLUST-ER	12- RER
Person-months per Participant	0.4	0.1	0.4	0,1
Participant number & acronym	13 – ART-ER	14- EWI	15- Biovia	16 – IA Lithuania
Person-months per Participant	0,4	0,4	2,8	0,4
Participant number & acronym	17- BRG	18- EATRIS	19- POP	20- ACCIÓ
Person-months per Participant	2	0,3	1	0,8
Participant number & acronym	21 – FORTH ICS	22- KRITI	23- SSP	24- RIMC
Person-months per Participant	0,2	0,2	3,5	0,1

<sup>3</sup> A transfer of PM from NE RDA to Biocat will be effective in Y2. Biocat will pass from 1 to 5 this period

<sup>4</sup> A transfer of PM from NE RDA to Biocat will be effective in Y2. NE RDA will pass from 10,4 to 6,4 in this period.

<b>Participant number &amp; acronym</b>	25- ASTRAZENECA			
<b>Person-months per Participant</b>	0,4			
<b>Start month</b>	M13: July 2025	<b>End month</b>	M24: June 2026	
<b>Objectives:</b> <ul style="list-style-type: none"> <li>➤ To implement the PRECISEU Dissemination and Communication Plan.</li> <li>➤ To enhance the visibility and to raise awareness of the project’s activities, results, and core messages.</li> <li>➤ To develop the PRECISEU project’s platform.</li> <li>➤ To contribute to the long-term and sustainable engagement of stakeholders and interested regional actors.</li> <li>➤ To ensure the exploitation and upscaling of the project’s methods and outcomes.</li> <li>➤ To enable and improve the communication between the regions and the stakeholders involved in the project.</li> </ul>				
<b>Description of Programmed Activities</b> <b>T2.1 Development and implementing the Communication Plan (M13-M24)</b> - Partners involved: NERDA (Lead), All partners  <p>NE RDA will continue to organise monthly meetings of the WP2 task force (last Thursday of each month at 13 CET) in order to coordinate the implementation of PRECISEU Dissemination and Communication activities.</p> <p>In line with the planned actions for the second year, the WP2 team will develop and implement concise media plans for each key milestone or activity. To maintain a coherent and structured communication approach, each planned external communication action will be detailed in the internal tool, the PRECISEU Social Media Content Plan. This instrument serves as a central hub, allocating a dedicated section for each major milestone or activity, with corresponding written and visual content prepared in advance to support visibility and engagement.</p> <ul style="list-style-type: none"> <li>➤ For each key milestone or activity, the WP2 team will: <ul style="list-style-type: none"> <li>● Develop a concise media plan following a debriefing call with the relevant WP team.</li> <li>● Detail the communication actions in the internal tool, PRECISEU Social Media Content Plan, which serves as a central hub for organizing communication efforts.</li> </ul> </li> <li>➤ The Social Media Content Plan includes: <ul style="list-style-type: none"> <li>● A dedicated section for each milestone/activity.</li> <li>● Pre-prepared written and visual content to ensure consistency and clarity.</li> </ul> </li> <li>➤ Visual materials are: <ul style="list-style-type: none"> <li>● Created by or in collaboration with Biocat team.</li> </ul> </li> <li>➤ Main communication channels and formats include: <ul style="list-style-type: none"> <li>● Social media posts (LinkedIn and Facebook) with engaging content.</li> <li>● Dedicated articles published on the PRECISEU website.</li> <li>● External newsletter, 1 every 3 months</li> </ul> </li> </ul>				

- For high-visibility events (e.g., PRECISEU Best Practice Recognition Ceremony):
  - The WP2 team will create dedicated LinkedIn events.
  - Live streaming may be organized to increase outreach and engagement

Additionally, the team will devote website posts to partners to highlight their work and to disseminate interesting news related.

**T2.2 Communication and dissemination toolkit (M13-M624)** - Partners involved: NERDA (Lead), All partners

- Development of the PRECISEU external newsletter (M15, M18, M21, M24)

A digital newsletter is prepared and distributed every three months using Mailchimp, ensuring regular and professional outreach to PRECISEU's target audiences.

- Each edition of the PRECISEU newsletter focuses on:

Promoting key project milestones and actions.

Showcasing best practice examples collected through project activities.

- Highlighting relevant events, including both internal PRECISEU initiatives and external opportunities relevant to the ecosystem.
- Content development is coordinated by NERDA with input from all partners, ensuring:
  - The inclusion of timely and relevant updates from across work packages.
  - Consistency with the wider Communication Plan and alignment with the Social Media Content Plan.
- The structure of each newsletter typically includes:
  - A project highlights section (e.g. milestone reached, new tool or service developed).
  - A featured best practice or partner success story.
  - Upcoming events and engagement opportunities.
  - Links to recent articles, resources, or social media content.
- The newsletter is:
  - Designed and formatted in Mailchimp, using PRECISEU's visual identity.

Sent to a growing list of stakeholders, policy makers, practitioners, and interested members of the public.

- Archived on the PRECISEU website for reference and transparency.
- Partners are encouraged to:

Share the newsletter via their own communication channels.

- Contribute regularly with relevant content or dissemination opportunities.

**T2.3 Promotion of the PRECISEU project activities (M13-M24)** - Partners involved: NERDA (Lead), All partners

- Develop and maintain the PRECISEU media plan aligned with the project events, milestones and work packages highlights
- Publish updates related to project events, milestones and work packages highlights within the PRECISEU LinkedIn account
  - PRECISEU open call will be promoted in strong connection with WP9
  - PRECISEU Summer Schools
  - PRECISEU Best Practice Recognition
  - PRECISEU ATMP map

- Visual content creation: develop infographics, cards and short videos to increase engagement and highlight the PRECISEU messages
- Continuous update of the Personalised Medicine events calendar and promotion of PRECISEU participation during the most relevant ones, such as:
  - Life Sciences Baltics event (M15)- PRECISEU GAM
  - Nordic Life Sciences event (M16)
  - Life Science Investors' Day 2025 Heidelberg (M16)
  - Life- the biomedical convention 2026, Heidelberg (M20)
  - Spinoff Conference Bulgaria (M24)-PRECISEU GAM

#### T2.4 Setting up, Launching, and curating the PRECISEU website (M13-M24)- Partners involved: Biocat

- To continue the development of the PRECISEU project's platform functionalities
- Content strategy development and implementation

#### Additional Deliverables (if applicable- brief description and month of delivery)

*Not applicable.*

### FOR WP3 – IA LITHUANIA

Set of Activities Number	WP3	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Interregional Collaboration and Partnership Bridging			
Participant number & acronym	1- Biocat	2 – SALUT	3 – BSC CNS	4- BIORN
Short Person-months per Participant	3,31	0,66	0,93	1,76
Participant number & acronym	5- BIOPRO	6 – NE RDA	7- DIZNE	8 – IMAGO-MOL
Short Person-months per Participant	0,44	0,57	0,,1	0,1
Participant number & acronym	9– HLSCB	11- CLUST-ER	13 – ART-ER	14- EWI
Short Person-months per Participant	0,25	1.14	0,46	1,76
Participant number & acronym	15 – Biovia	16 – IA Lithuania	17 – BRG	18- EATRIS
Short Person-months per Participant	6,83	17	2,28	2,79
Participant number & acronym	19 – POP	20 – ACCIO	21 – FORTH	22- KRITI
Short Person-months per Participant	4,57	1,24	3,72	0,31

<b>Participant number &amp; acronym</b>	23- SSP	24- RIMC	25 ASTRAZENECA	-
<b>Short Person-months per Participant</b>	0,46	0,10	2,86	
<b>Start month</b>	M13: July 2025	<b>End month</b>	M24: June 2026	
<b>Objectives:</b> <ul style="list-style-type: none"> <li>To foster connections between regions and complement the main international PM driving initiatives;</li> <li>Actively contribute to advances in PM-related policy development within the framework of the Presidencies of the European Union. This includes participating in events related to the Danish and Cypriot Presidencies in the second year, as well as preparing PM case studies for countries hosting the Presidency.</li> </ul>				
<b>Description of Programmed Activities</b> <ul style="list-style-type: none"> <li>T3.1 Partner regions landscape (M1-M16)- Partners Involved: IA Lit (lead), FORTH, Clust-ER Deliverable 3.1 Initiatives mapping (M16)</li> <li>T3.2 Connect and complement main international PM driving initiatives (M1-M58)- Partners involved: Biovia, BRG, FORTH, EWI</li> </ul> <p>Visit or connect activity being undertaken across the EU to fulfil the PM driven healthcare transformation in Europe (M18/M24) Biovia.</p> <p>In accordance with the prepared PM initiatives mapping (IA Lithuania D3.1), Biovia will lead the visits or connection activities (M18/M24). The objective is not only to make PRECISEU visible in the political landscape, but also, more importantly, to fulfil PM-driven healthcare transformations in Europe. Find links and synergies with other initiatives to avoid duplication and increase interoperability. Visit or connection activity directly related to the:</p> <ul style="list-style-type: none"> <li>- identification of potential synergies of PM initiatives;</li> <li>- identification of regional healthcare transformation strategies and S3 principles and methodologies;</li> <li>- identification of related initiatives, research infrastructures and capacities.</li> </ul> <ul style="list-style-type: none"> <li>T3.3 Multistakeholder Alignment (M16-M58)- Partners involved: BRG, FORTH, POP, AZ</li> </ul> <p>Event linked to the Cyprus Presidency of the Council of the European Union (M24). Biocat and BRG will lead the involvement of PRECISEU to become involved in the Cyprus EU Presidency. The objective of this is not only that PRECISEU is made visible in the political landscape, but more importantly that the topic of PM, in relation with advanced therapies and the secondary use of health data is brought to the table and defended by leading experts in the field. By doing this, PRECISEU will walk towards a common approach at the European level to address PM.</p> <p>This work implies:</p> <ul style="list-style-type: none"> <li>- Identifying organisations and/or people involved in the definition of the agenda of the Cyprus Presidency.</li> <li>- Exploration of the existing agenda of the Presidency and identification of suitable spaces to represent PRECISEU.</li> <li>- Reach an agreement with authorities or other entities responsible of hosting an event, to either (co)organise an event or to represent PRECISEU on the stage.</li> <li>- Exploit existing relationships of the consortium in Cyprus to identify local experts that may</li> </ul>				

<p>contribute to the discussion.</p> <ul style="list-style-type: none"> <li>- Organise / take part in the event, in representation of the consortium and bringing in relevant local players.</li> <li>- Collect and share with the whole consortium the outputs of the event. <ul style="list-style-type: none"> <li>• T3.4 Scaling up the dialog on ATMPs / PM at Policymaking related fields (M1-M58)- Partners involved: Biocat (lead), FORTH, Eattris</li> </ul> </li> </ul> <p>Deliverable 3.4 Case Study Denmark (M16) and Event linked to the Danish Presidency of the Council of the European Union (M18).</p> <p>Biocat and FORTH-ICS will oversee PRECISEU's involvement in the Danish EU Presidency. This will make PRECISEU visible in the political landscape and, more importantly, bring the topic of PM in relation to advanced therapies and the secondary use of health data to the table, where it will be defended by leading experts in the field. This will enable PRECISEU to take a step towards a common European approach to address PM.</p> <p>This work involves:</p> <ul style="list-style-type: none"> <li>- Identifying organisations and/or individuals involved in defining the agenda of the Danish Presidency.</li> <li>- Exploring the existing agenda of the Presidency and identifying suitable spaces in which to represent PRECISEU.</li> <li>- Reaching an agreement with the relevant authorities or entities to either co-organise or host an event, or to represent PRECISEU at the event.</li> <li>- Exploit existing relationships within the consortium in Denmark to identify local experts who may contribute to the discussion.</li> <li>- Organise/take part in the event in the consortium's representation, bringing in relevant local players.</li> <li>- Collect and share the outputs of the event with the whole consortium.</li> </ul> <p>Deliverable 3.5 Case Study Cyprus (M21) and Event linked to the EU Presidency: In preparation with TEHDAS2 to be held on May 2026.</p> <ul style="list-style-type: none"> <li>• T3.5 Ethical, Legal and Societal Implications (ELSI) (M1-M58)- Partners involved: EATRIS (lead), BSC, FORTH</li> </ul> <p>There is not a deliverable linked to this task, but the Guidelines will be shared in the General Assemblies # 3 and 4 (onsite and online, respectively). The outcomes will be used for the T7.4 activities.</p> <p>Milestone No.7- Advisory group set-up with representatives of relevant initiatives and experts in PM: BRG (M16).</p> <p><b>Additional Deliverables</b> (if applicable- brief description and month of delivery)  <i>Not applicable.</i></p>
--

### FOR WP4 – ART-ER

Set of Activities Number	WP4	Start Date or Starting Event	M13: July 2025
Set of Activities Title	Use of Health Data		

Participant number & acronym	1 – Biocat	2 – SALUT	3 – BCS CNS	4 – BIORN
Short Person-months per Participant	0,2	0,2	8	0,1
Participant number & acronym	5 – BIOPRO	11 – CLUST-ER	12 – RER	13 – ART-ER
Short Person-months per Participant	3,2	1	0,3	4,4
Participant number & acronym	15 – Biovia	16–IA LITHUANIA	17- BRG	18- EATRIS
Short Person-months per Participant	1	0,2	0,2	1,8
Participant number & acronym	19- POP	21- FORTH	22- SSP	23- RIMC
Short Person-months per Participant	0,2	4,6	0,2	0,04
Participant number & acronym	25- ASTRAZENECA			
Short Person-months per Participant	0,2			
Start month	M13: July 2025	End month	M24: June 2026	
<b>Objectives (Second year):</b> <ul style="list-style-type: none"> <li>• Task 4.1 <ul style="list-style-type: none"> <li>○ Understand the requirements for the EHDS and the Regions regarding the use of health data.</li> </ul> </li> <li>• Task 4.2- 4.4 <ul style="list-style-type: none"> <li>○ Create an interoperability framework to enable secure, standardized, and seamless data sharing and integration to support collaborative health research and innovation.</li> <li>○ Create guidance documentation to support the Regions in developing cross-border projects using standardized, secure, compliant and FAIR data management.</li> </ul> </li> </ul>				
<b>Description of Programmed Activities</b> <ul style="list-style-type: none"> <li>• <b>T4.1 Assessing Readiness to EHDS (M1-M15) - Partners involved: BIOPRO (Lead), ART-ER, CLUST-ER HEALTH, FORTH</b>  Coordinate the partners for the finalization of the report regarding the readiness of EHDS in Europe (PRECISEU-countries)  This activity involves a distribution of effort for the completion of the different paragraphs of the report according to a plan agreed between BIOPRO and the partners of task 4.1.   The most relevant actions are however the conversion of the country GMM into a discursive text that can represent the status-quo of EHDS readiness for each PRECISEU country.</li> </ul>				

The partners will also check the contents of the different country factsheets that will be included as annexes to the report.

Partners will hold short meetings every week to check the progress of the finalisation of the EHDS assessment report and the achievement of D4.1 foreseen for the end of September.

- **T4.2 Requirements and tools for data storage and data processing in the EHDS (M7-M20) - Partners involved: BSC (Lead), ART-ER, FORTH**

Identify relevant concepts (requirements, best practices, tools) in the literature related to the topics of Tasks 4.2 (data access, storage, and secure processing).

Conduct interviews with experts to obtain complementary evidence on the topics addressed in Tasks 4.2 (data access, storage, and secure processing). If interviews cannot be arranged, surveys will be employed as an alternative method of data collection.

- **T4.3 Technical, Syntactic, and Semantic Interoperability: from standards to FAIR by design approaches (M7-M20) - Partners involved: BSC (Lead), CLUST-ER HEALTH, FORTH**

Identify relevant concepts in the literature related to the topics of Task 4.3 to define a solid approach for ensuring interoperability.

Conduct interviews with experts to obtain complementary evidence on the topics addressed in Task 4.3 (interoperability). If interviews cannot be arranged, surveys will be employed as an alternative method of data collection.

Produce the Interoperability Framework (D4.2), outlining key enablers across different interoperability dimensions around different stages of the data life cycle under the FAIR (Findable, Accessible, Interoperable, and Reusable) principles.

- **T4.4 Guidelines for the activation of Joint Interregional Projects in Personalised Medicine (M13-M20) – Partners involved: BSC (Lead), CLUST-ER HEALTH, BIOPRO, EATRIS**

Produce the Guidelines for JIPs (D4.3) and the final DMP for JIPs (D4.4) using the evidence gathered in T4.2 and T4.3.

Although task 4.4 was supposed to start in July 2025, some activities were undertaken between February and June 2025, because it was necessary to harmonise the structure of the guidelines with the DMP for JIPs.

The guidelines will include an introduction (purpose of the guidelines, target audience, definition and rationale for joint projects) and then recommendations and suggestions for the development of Joint Interregional Projects on Personalised Medicine, and input to highlight the benefits of primary and secondary use of health data for EU citizens, preserving privacy in data processing environments and data interoperability in an EHDS-like scenario.

The guidelines sections will be linked to the research data lifecycle (as in the other deliverables) and the data management plan model.

Specifically, it is planned to have by July a first draft of a table of contents for the guidelines document on which to involve the different task's partners in its elaboration with a division of effort.

The first draft of the guidelines is to be elaborated by October 2025 and afterwards all partners will be involved in the revision of the document to reach the final version by December 2025.

**Additional Deliverables** (if applicable- brief description and month of delivery)

*Not applicable.*

## FOR WP5- BIOPRO

Set of Activities Number	WP5	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Multistakeholder infrastructure to enable access to ATMP on large scale			
Participant number & acronym	1 – Biocat	2 – SALUT	4 – BIORN	5- BIOPRO
Short Person-months per Participant	0,2	1	8,2	7,7
Participant number & acronym	11 – CLUST-ER	12 – RER	13 – ART-RER	15- Biovia
Short Person-months per Participant	1,2	0,2	0,4	6,4
Participant number & acronym	16 – IA Lithuania	17 – BRG	18 – EATRIS	19- POP
Short Person-months per Participant	0,2	3,4	5,6	3,4
Participant number & acronym	21 – FORTH-ICS	23- SSP		
Short Person-months per Participant	3	2,34		
Start month	M13: July 2025	End month	M24: June 2026	
<p><b>Objectives:</b></p> <ol style="list-style-type: none"> <li><b>1. Create a virtual ATMP ecosystem (D5.2, D5.3, D5.4):</b>  <u>Kicking off virtual ATMP ecosystem</u>  Establishment of a virtual ecosystem to facilitate the exchange of best practices among ATMP hubs/centres across Europe, promoting harmonization in standard ATMP development. This initiative will commence with a pan-European panel/workshop focused on early innovation and regulation of ATMPs during the Festival of Biologics in Basel, followed by a virtual workshop that brings together various ATMP hubs to discuss shared challenges. During this workshop the key ingredients of a successful ATMP hub/centre can be defined as well.</li> <li><b>2. Identify actors involved in ATMP development (D5.1, D5.5)</b>  Scouting potential early-stage collaborations, potential users of ATMP infrastructure/capacities  Through utilization of networks and analysis/research potential partners for collaboration pilots and infrastructure users will be identified, approached, and supported in running collaboration and/or using infrastructure.</li> <li><b>3. Create a well-populated and well-curated ATMP capacity map and bring capacities to use (D5.1, D5.2, D5.3, D5.4)</b> <ul style="list-style-type: none"> <li>• Expansion and development of the ATMP capacity map</li> </ul> </li> </ol>				

<p>Regular updates and expansion into additional EU regions to comprehensively represent the broader European landscape. A targeted marketing campaign will be launched to engage industry stakeholders across the entire value chain of ATMP development.</p> <ul style="list-style-type: none"> <li>Strategic promotion of PRECISEU ATMP infrastructure capacities</li> </ul> <p>These capacities will be showcased at international conferences, enabling companies to access integrated capacities essential for developing their products, incl. running clinical trials.</p>
<p><b>Description of Programmed Activities</b></p> <p><b>T5.1 State of the art of ATMPs development and production in EU (M1-M12)- Partners involved: EATRIS (Lead), Clust-ER Health, BRG</b></p> <ul style="list-style-type: none"> <li>Task 5.1 ends with D5.1 in June 2025, but the ATMP map will continue to be supplemented by ATMP organisations across Europe. The ATMP map will be launched on the PRECISEU website in September 2025 and will be an ongoing process.</li> <li>Expansion and regular updates of the ATMP capacity map to include more EU regions. A targeted marketing campaign will engage industry stakeholders across the ATMP value chain.</li> </ul> <p><b>T5.2 Multistakeholder Infrastructure for development, production, and use/implementation of ATMPs (M6-M24)- Partners involved: BioRN (Lead), Clust-ER Health, BIOPRO, EATRIS</b></p> <ul style="list-style-type: none"> <li>Establish a virtual ecosystem for ATMP hubs across Europe to exchange best practices and promote harmonization. Start with a pan-European panel at the Festival of Biologics in Basel, followed by a virtual workshop to discuss shared challenges and define key success factors for ATMP hubs.</li> </ul> <p><b>T5.3 Enable access and growth of the open infrastructure for ATMPs (M12-M42)- Partners involved: BioRN (Lead), SSP, Clust-ER Health, BioRN, BRG, EATRIS</b></p> <ul style="list-style-type: none"> <li>Scouting early-stage collaborations and potential ATMP infrastructure users by leveraging networks and research to identify, approach, and support suitable partners.</li> </ul> <p><b>T5.4 Facilitate patients access to ATMPs (M18-M60)- Partners involved: BIOPRO (Lead), Biovia, SSP, RER, Departament de Salut, EATRIS, FORTH</b></p> <ul style="list-style-type: none"> <li>Strategic promotion of PRECISEU ATMP infrastructure at international conferences to enable companies to access integrated capacities for product development and clinical trials.</li> </ul>
<p><b>Additional Deliverables</b> (if applicable- brief description and month of delivery)</p> <p><i>Not applicable.</i></p>

## FOR WP6 – SAHLGRENKA SCIENCE PARK

Set of Activities Number	WP6	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Market and Patient Access			
Participant number & acronym	1 – Biocat	2 – SALUT	4 – BIORN	5- BIOPRO
Short Person-months per Participant	0,2	1,4	0,8	3,2

Participant number & acronym	6 – NE RDA	7 – DIZNE	8 –IMAGO-MOL	9 – HLSCB
Short Person-months per Participant	0,6	0,2	0,6	0,6
Participant number & acronym	11 – CLUST-ER	12- RER	13 – ART-ER	14- EWI
Short Person-months per Participant	1	0,3	0,4	0,4
Participant number & acronym	15 – Biovia	16 – IA Lithuania	17 – BRG	18 – EATRIS
Short Person-months per Participant	4	1	0,06	1,8
Participant number & acronym	20- ACCIO	21 – FORTH-ICS	23 – SSP	24- RIMC
Short Person-months per Participant	1,6	3,6	10,6	0,08
Participant number & acronym	25- ASTRAZENECA			
Short Person-months per Participant	3,6			
Start month	M13: July 2025	End month	M24: June 2026	
<b>Objectives:</b> <ul style="list-style-type: none"> <li>• <u>Communication</u>: Raising awareness among stakeholders in the personalised medicine ecosystem—including decision-makers and policymakers—about regional differences and commonalities in health data regulation, barriers to ATMP development, and challenges related to innovation uptake (based on D6.1).</li> <li>• <u>Actions</u>: Develop and define cross-market collaboration and harmonization models for personalised medicine to accelerate innovation implementation, including testbed partnerships, sustainable business models, and regulatory and market access strategies aligned with local and EU authorities.</li> </ul>				
<b>Description of Programmed Activities</b> <ul style="list-style-type: none"> <li>• T 6.1 Mapping and nailing main restraints for implementation of Precision care in each region (M1-M15). Finalising report delivery. <ul style="list-style-type: none"> <li>○ Based on input from a wide range of stakeholders across Europe—including healthcare professionals, industry representatives, SMEs, patients, regulators, and investors—gathered by PRECISEU country representatives and documented in regional reports, the following insights have been synthesized for the cross-regional report. <ul style="list-style-type: none"> <li>▪ Highlights common and region-specific challenges, including data access, regulation, financing, and system readiness</li> <li>▪ Good practices and scalable local initiatives</li> <li>▪ Regional overviews with insights on strengths, weaknesses, and the current state of personalised medicine.</li> </ul> </li> </ul> </li> </ul> <p>SSP, as the lead for WP6, is coordinating the finalisation of the deliverable, including the drafting of the introduction and methodology sections. In collaboration with EATRIS, SSP is also</p>				

summarising the key barriers. Biovia and BioPRO are responsible for structuring and writing the good practice section, while FORTH is preparing the country fact sheets. ACCIÓ and AstraZeneca will conduct the first internal review.

- T6.2 Develop model and roadmap for best implementation of Precision care (M12-M58)- Partners involved: ACCIÓ, AstraZeneca, BIOPRO, EATRIS, FORTH, Biovia.
  - Create awareness and visualise key differences and commonalities across stakeholder groups regarding market access, finance, regulatory, data, and ATMP-related challenges, captured in D6.1, though tailored summary briefs with key insights and stakeholder specific implications, newsletters and PM school, webinars. Creation of a summary brief or statement, addressing EU-policy makers, to bridge project-level insights with EU-level policy development (in collaboration with WP 3).
  - Celebrate the Hackathon finale with Nordic Life Sciences Days.
  - Building on the results of Deliverable 6.1, WP6 will develop a roadmap aimed at accelerating the implementation of personalised care.
    - In the first four months, key topics and questions will be selected and assigned to WP6 partners,
    - WP Partners will gather expert input on practical steps to tackle the challenges, which will be summarized in a roadmap (between months 17 and 24).The roadmap will include actions at the regional, national, and EU levels.
    - To ensure alignment with WP4 (Health Data), WP5 (ATMP) and WP8 (Procurement and implementation into Healthcare), incorporation of their inputs will be implemented.
    - In parallel with the development of the roadmap, WP6 partners will evaluate potential approaches for establishing the open innovation collaboration model. This work will be conducted in close cooperation with Work Package 3 and other relevant work packages focused on building long-term structures to support European collaboration, such as WP5. The resulting analysis will provide a crucial foundation for developing the open innovation collaboration model during the third year of the project.

**Additional Deliverables** (if applicable- brief description and month of delivery)

## FOR WP7 – HEALTH AND LIFE SCIENCES CLUSTER BULGARIA

Set of Activities Number	WP7	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Training and Cultural Change			
Participant number & acronym	1 – Biocat	2 – SALUT	4 – BIORN	5 – BIOPRO
Short Person-months per Participant	3	1	3	1,8
Participant number & acronym	6 – NE RDA	7- DIZNE	8 –IMAGO-MOL	9- HLSCB

Short Person-months per Participant	0,9	1,8	0,9	7,8
Participant number & acronym	11 – CLUSTER	13 – ART-ER	14 – EWI	15- Biovia
Short Person-months per Participant	0,6	0,2	0,2	1
Participant number & acronym	16 – IA LITHUANIA	18– EATRIS	19- POP	20- ACCIÓ
Short Person-months per Participant	1	0,2	3,2	0,4
	23 – SSP	24 – RICM	25 – ASTRAZENECA	-
	1	0,06	1,5	
Start month	M13: July 2025	End month	M24: June 2026	
<b>Objectives:</b> <ul style="list-style-type: none"> <li>• Build capacity and foster a culture of innovation and collaboration in personalised medicine (PM) across PRECISEU regions.</li> <li>• Develop and disseminate resources, training, and best practices to support the adoption and scaling of PM.</li> <li>• Recognize and accelerate outstanding regional initiatives and support evidence-based policymaking.</li> </ul>				
<b>Description of Programmed Activities</b> <b>T7.1 Repository for Capacity Building (M1–M58)</b> Partners involved: HLSCB (Lead), NE RDA, Rivne <ul style="list-style-type: none"> <li>• Maintain and expand a functional repository on the PRECISEU platform, offering resources, decision-making tools, educational materials, and links to best practices and complementary initiatives.</li> <li>• Update content based on partner contributions, user feedback, and evolving project needs.</li> <li>• Ensure the repository supports ongoing training, knowledge transfer, and capacity building for all stakeholders.</li> </ul> <b>T7.2 PRECISEU Best Practice Recognition (M3–M56)</b> Partners involved: BioRN (Lead), Dizne, POP <ul style="list-style-type: none"> <li>• Operate the Best Practice Recognition programme, including the management of calls, evaluation, and recognition of outstanding PM initiatives.</li> <li>• Promote the programme through targeted communication campaigns, info sessions, and stakeholder engagement.</li> <li>• Organize the recognition ceremony and disseminate success stories and lessons learned to inspire further innovation.</li> </ul>				

<p>T7.3 Training Program (M12–M56)</p> <p>Partners involved: Dizne (Lead), Biovia, EATRIS, HLSCB</p> <ul style="list-style-type: none"> <li>• Design, implement, and refine interactive and tailored training modules for professionals in health and life sciences.</li> <li>• Pilot and evaluate training formats (online, hybrid, in-person) and integrate feedback for continuous improvement.</li> <li>• Organize the PRECISEU PM Schools and other flagship training events to foster peer learning and skills development.</li> </ul> <p>T7.4 Transforming Policymaking (M12–M52)</p> <p>Partners involved: Biocat (Lead), Salut, Clust-ER, POP</p> <ul style="list-style-type: none"> <li>• Develop, pilot, and disseminate innovative guidelines and approaches for evidence-based policymaking in PM.</li> <li>• Engage policymakers and stakeholders through workshops, peer-learning activities, and targeted dissemination of the Biodesign Guidelines for Policymakers.</li> <li>• Monitor and evaluate the impact of the guidelines and support their adoption across regions.</li> </ul> <p><b>Additional Deliverables (if applicable- brief description and month of delivery)</b></p> <p><i>Not applicable.</i></p> <ul style="list-style-type: none"> <li>•</li> </ul>
---

## FOR WP8 –SALUT (HEALTH DEPARTMENT, CATALONIA)

Set of Activities Number	WP8	Start Date or Starting Event	M13: July 2025	
<b>Set of Activities Title</b>	<b>Adoption of PM innovations in the HealthCare System</b>			
Participant number & acronym	1 – Biocat	2 – SALUT	3 – BSC CNS	4- BIORN
Short Person-months per Participant	0,4	10,8	0,4	2
Participant number & acronym	5- BIOPRO	6 – NE RDA	8 – IMAGO-MOL	10- SIA
Short Person-months per Participant	0,2	1	0,2	0,3
Participant number & acronym	12- RER	13 – ART-ER	14- EWI	15 – Biovia
Short Person-months per Participant	0,3	0,2	0,2	2
Participant number & acronym	16 – IA Lithuania	19 – POP	21 – FORTH-ICS	22- KRITI

Short Person-months per Participant	1	0,1	2,5	0,2
Participant number & acronym	23 – SSP	24- RIMC	25 - ASTRAZENECA	
Short Person-months per Participant	2,2	0,1	0,2	
Start month	M13: July 2025	End month	M24: June 2026	
<b>Objectives:</b> <ol style="list-style-type: none"> <li>1. Identify and analyse initiatives in PRECISEU regions/partners that illustrate the strategic approach taken with regards to reimbursement/procurement of PM interventions</li> <li>2. Identify and analyse documents/initiatives in PRECISEU regions/partners that illustrate the strategic approach taken with regards to organizational models of the regional health systems for PM deployment</li> <li>3. Identify and analyse initiatives in PRECISEU regions/partners that could illustrate examples of reimbursement/ procurement models and systemic organizational schemes to enable PM deployment</li> </ol>				
<b>Description of Programmed Activities</b> <ul style="list-style-type: none"> <li>• T8.1 Reimbursement and procurement models for PM (M1-M52)- Partners involved: SALUT (Lead), BioRN, Biovia <ul style="list-style-type: none"> <li>○ Reach a consensus for the proposed methodology for WP8 activities: <ul style="list-style-type: none"> <li>□ Perform a comprehensive literature review: including the assessment of information from initiatives and available public documents in the different regions of the Consortium and at EU level</li> <li>□ Perform a set of stakeholder interviews to complement the literature review, considering the experts appointed by every partner/region</li> </ul> </li> <li>○ Run and internal validation of the results obtained in the literature review and the interviews (external validation will be done in subsequent years, as part of the planned recurrent updates)</li> <li>○ Draft the reporting of results and the related corresponding deliverable (D8.1) Review and submit Deliverable (D8.1), according to the process defined for the Consortium. (M18)</li> </ul> </li> <li>• T8.2 PM pathways in the clinical practice (M2-M52)- Partners involved: SALUT (Lead) <ul style="list-style-type: none"> <li>○ Reach a consensus for the proposed methodology for WP8 activities: <ul style="list-style-type: none"> <li>□ Perform a comprehensive literature review: including the assessment of information from initiatives and available public documents in the different regions of the Consortium and at EU level</li> <li>□ Perform a set of stakeholder interviews to complement the literature review, considering the experts appointed by every partner/region</li> </ul> </li> <li>○ Run and internal validation of the results obtained in the literature review and the interviews (external validation will be done in subsequent years, as part of the planned recurrent updates)</li> <li>○ Draft the reporting of results and the related corresponding deliverable (D8.2)</li> </ul> </li> </ul>				

- Review and submit Deliverable (D8.2), according to the process defined for the Consortium.(M18)
- T8.3 Maturity assessment of PM innovations towards value-based adoption in the healthcare system (M12-M52)- Partners involved: SALUT (Lead), FORTH
  - Reach a consensus for the proposed methodology for WP8 activities:
    - Perform a comprehensive literature review: including the assessment of information from initiatives and available public documents in the different regions of the Consortium and at EU level
    - Perform a set of stakeholder interviews to complement the literature review, considering the experts appointed by every partner/region
  - Run and internal validation of the results obtained in the literature review and the interviews (external validation will be done in subsequent years, as part of the planned recurrent updates)
  - Draft the Reporting of results and the related corresponding deliverable (D8.3) drafting
  - Review and submit Deliverable (D8.3), according to the process defined for the Consortium. review and submission (M18).

**Additional Deliverables** (if applicable- brief description and month of delivery)

*Not applicable.*

## FOR WP9 – BIOCAT

Set of Activities Number	WP9	Start Date or Starting Event	M13: July 2025	
Set of Activities Title	Innovation Support Program			
Participant number & acronym	1 – Biocat	2 – SALUT	3- BSC	4 – BIORN
Short Person-months per Participant	5,4	1	0,1	1
Participant number & acronym	5- BIOPRO	6 – NE RDA	7- DIZNE	9 – HLSCB
Short Person-months per Participant	2,5	0,6	0,8	0,6
Participant number & acronym	10 – SIA	11 – CLUST-ER	12- RER	13 – ART-ER
Short Person-months per Participant	0,3	0,2	3,2	0,2
Participant number & acronym	15 – Biovia	16 – IA Lithuania	20- ACCIO	21 – FORTH-ICS
Short Person-months per Participant	4,2	0,8	5,2	0,2

Participant number & acronym	22 – KRITI	23 – SSP	25 – ASTRAZENECA	
Short Person-months per Participant	0,8	0,6	6,1	
Start month	M13: July 2025	End month	M24: June 2026	
<b>Objectives:</b> <ul style="list-style-type: none"> <li>• <b>Successfully launch and manage the PRECISEU Open Call for Joint Interregional Projects</b>, ensuring operational coordination of the FSTP scheme across participating regions.</li> <li>• <b>Support applicants through the mentoring, funnelling and matchmaking process</b>, enabling the creation of strong, cross-regional consortia aligned with project priorities.</li> <li>• <b>Ensure strategic coherence</b> by guiding applicants and funding agencies throughout the call process and coordinating evaluation and selection in alignment with WP3–WP8.</li> </ul>				
<b>Description of Programmed Activities</b> <p><b>T9.2 Topic and participant funnelling action (M1-M20)- <i>Partners involved: ACCIÓ (Lead), Biocat, Biovia, SSP</i></b></p> <ul style="list-style-type: none"> <li>• Implement and coordinate the <b>mentoring and funnelling process</b> for applicants who submitted an Expression of Interest (EoI), supporting the maturation of project ideas.</li> <li>• Organise <b>matchmaking and brokerage events</b> to foster the creation of high-quality, cross-regional consortia.</li> <li>• Provide personalised <b>non-financial support</b> to applicants, including guidance on proposal refinement, partner search, and alignment with regional and EU priorities.</li> <li>• Track regional engagement in the funnelling phase and ensure balanced participation aligned with funding availability.</li> <li>• Prepare applicant-facing resources and documentation ahead of the Open Call (e.g. FAQs, templates, summary of national requirements).</li> </ul> <p><b>T9.3 FSTP administrative and financial processes (M20-M56) - <i>Partners involved: Biocat (Lead), ACCIO, BioPRO, RER, KRITI, NERDA</i></b></p> <ul style="list-style-type: none"> <li>• Finalise the <b>launch and management</b> of the Open Call for Joint Interregional Projects (Nov–Dec 2025), ensuring full compliance with FSTP rules.</li> <li>• Coordinate with regional funding agencies to manage their respective <b>national/regional appendices</b> and administrative obligations.</li> <li>• Set up the <b>evaluation and selection process</b>, including recruitment of independent experts and drafting of supporting documents (evaluation forms, guidance for reviewers, etc.).</li> <li>• Provide procedural and technical support to applicants and funding bodies throughout the application and evaluation phases.</li> <li>• Begin preparation for the <b>grant agreement phase</b> with selected projects, ensuring alignment with PRECISEU legal and financial frameworks.</li> </ul>				

**T9.4 Project monitoring and quality and outcome assessment (M24-M60) - partners involved: ACCIÓ (Lead), BSC, BIOPRO, Clust-ER, Biocat**

- Define the monitoring methodology and assign monitoring partners for the funded JIPs.
- Prepare templates and tools for **project performance tracking**, including technical progress, financial execution, and expected outcomes.
- Design the structure for **semi-annual monitoring meetings** and ad hoc follow-ups with project coordinators.
- Begin planning for the **impact assessment framework**, to be applied throughout the implementation of the funded projects.

**Additional Deliverables** (if applicable- brief description and month of delivery)

*Not applicable.*

**Table 2.3.b: AWP List of Programmed Activities with PM of main players leading the action. The bulk participation of all partners appears in the last row.**

Activity #	Activity Title	Short name of lead participant	Person-months	Start Month	End Month
1	General Assembly onsite Vilnius	Biocat	1	13	15
2	General Assembly onsite Vilnius	IA Lith	0,3	13	15
3	General Assembly online	Biocat	0,5	20	21
4	General Assembly Onsite Sofia	Biocat	1	23	24
5	General Assembly Onsite Sofia	HLSCB	0,3	23	24
6	Financial Webinar	Biocat	0,5	16	16
7	Steering Committees Monthly	Biocat	2	12	24
8	Monthly Campaigns	NERDA	1,5	13	24
9	Monthly Campaigns	Biocat	1,2	13	24
10	Quarterly Newsletter	NERDA	0,5	13	24
11	Quarterly Newsletter	Biocat	0,5	13	24
12	Platform updates	Biocat	2	13	24
13, 14	Denmark and Cyprus Case Studies	IA Lithuania	3	13	24
15,16	Organisation / attendance EU events	Biocat	2	13	24
17,18	attendance EU events	IA Lith	1	13	24
19	Connect Activity to DK and UK	Biovia	3	18	20
20	EHDS Report	BIOPRO	2	13	24
21	Interviews and report	BSC	2	13	24
22	ATMP Map dissemination at events	Eatris	2	13	24
23	ATMP Map dissemination at events	Biocat	0,2	13	24

23	ATMP Map dissemination at events	Other partners accumulated	5	13	24
24	Mapping and summaries	SSP	2	13	24
25	Hackathon	SSP	3	16	17
26	Repository update	HLSCB	2	13	24
27	PRECISEU Recognition	BIOPRO	1,5	13	24
28	PRECISEU School	DIZNE	1,9	13	13
29	PRECISEU School	SSP	1	15	17
30	Transforming Policymaking	Biocat	3,2 <sup>5</sup>	13	24
31	PM Implementation	SALUT	3	13	24
32	Innovation Support Program	Biocat	5	13	24
33	Innovation Support Program	ACCIO	4	13	24
34	Funding JIPs	All partners	15	13	24
35-n	Other Y2 activities (non-public, nor programmed or with reduced efforts)	All partners	221	13	24

The calculation of PM in the table above corresponds to public or programmed activities plus the estimation of basal activities that will be performed by all partners in Y2, especially WP leads. The estimation corresponds to the average of PM per year used by the consortium. Deviations will be considered in the Progress Reports.

**Table 2.3.b2 (additional info): AWP PM per WP in the period**

Activity No + Title	Lead participant	PM per WP	Start Month	End Month
WP1 - Project Management and Coordination	Biocat	16,5	13	24
WP2- Communication, dissemination and exploitation	NERDA	27,2	13	24
WP3 - Interregional collaboration and ecosystem building	IA Lithuania	53,64	13	24
WP4 – Use of health data	ART-ER	25,84	13	24
WP5 – Multistakeholder infrastructure to enable access to ATMP on large	BIOPRO	43,64	13	24
WP6 – Market and Patient Access	SSP	39,24	13	24
WP7 – Training and Cultural Change	HLSCB	29,56	13	24
WP8 – Adoption of PM Innovations in the HealthCare System	SALUT	24,3	13	24
WP9 – Innovation Support Program	Biocat	34	13	24

<sup>5</sup> PMs necessary for Biocat for the pilot of DTPM 7.4 will be used from Y1 non-used for this task.

TOTAL	Consortium	295,25	13	24
-------	------------	--------	----	----

**Table 2.3.c: Annual Deliverables List (if applicable)**

Deliverable No	Deliverable Name	Activity No	Lead Participant	Type	Dissemination Level	Delivery Date
D1.5	Year 3 Annual Work Plan	NA	Biocat	R	Public	M24
D1.9	GEDI assessment and recommendations	NA	Biocat	R	Public	M24
D3.1	Initiatives Mapping	NA	IA Lithuania	R	Public	M16
D3.4	Case Study Denmark	13	IA Lithuania	R	Public	M15
D3.5	Case Study Cyprus	14	IA Lithuania	R	Public	M21
D4.1	PRECISEU readiness framework	20	BIOPRO	R	Public	M15
D4.2	Interoperability Framework	21	BSC CNS	R	Public	M20
D4.3	Guidelines for Joint Interregional Projects on Personalised Medicine	NA	BSC CNS	R	Public	M20
D5.2	Blueprint for Multi-stakeholder ATMP Infrastructure Access	NA	EATRIS	DEC	Public	M24
D5.3	Multi-stakeholders Infrastructure Service Catalogue	NA	BIORN	DEC	Public	M24
D5.4	Regulation and governance of the Multi-stakeholders Infrastructure	22, 23	EATRIS	R	Sensitive	M24
D6.1	Cross Regional Report	24	SSP	R	Public	M15
D7.1	Handbook Trainings	28,29	HLSCB	R	Public	M13
D7.2	Recognition	27	BIORN	R	Public	M13
D7.3	Guidelines Biodesign for Policymakers	30	Biocat	R	Public	M13

<b>D8.1</b>	Interim guidance: reimbursement models for PM	31	SALUT	R	Public	M18
<b>D8.2</b>	Interim guidance: structural and operational schemes	31	SALUT	R	Public	M18
<b>D8.3</b>	Interim guidance: value-based adoption	31	SALUT	R	Public	M18

## DELIVERABLE CODES

### TYPE

R: Document, report (excluding the periodic and final reports)

DEM: Demonstrator, pilot, prototype, plan designs

DEC: Websites, patents filing, press & media actions, videos, etc.

DATA: Data sets, microdata, etc.

DMP: Data management plan

ETHICS: Deliverables related to ethics issues.

SECURITY: Deliverables related to security issues

OTHER: Software, technical diagram, algorithms, models, etc.

### DISSEMINATION LEVEL

PU – Public, fully open, e.g. web (Deliverables flagged as public will be automatically published in CORDIS project’s page)

SEN – Sensitive, limited under the conditions of the Grant Agreement

Classified R-UE/EU-R – EU RESTRICTED under the Commission Decision No2015/444

Classified C-UE/EU-C – EU CONFIDENTIAL under the Commission Decision No2015/444

Classified S-UE/EU-S – EU SECRET under the Commission Decision No2015/444

DELIVERY DATE: Measured in months from the programme start date (month 1).

## 3.4 PARTNERS’ PARTICIPATION IN ANNUAL WORK PLAN ACTIVITIES

Does the participant plan to subcontract certain tasks (please note that core tasks of the programme should not be sub-contracted) (article 6.2 B and 9.3 of Model Grant Agreement (MGA))?	Y
<b>Biocat</b> Cost foreseen: 30.000 € (out of 150.000 €, lineal consumption)	

Biocat plans to subcontract external support services to assist in the coordination and operational follow-up of the PRECISEU project. This includes support in the development of the Annual Work Plan, the organisation and documentation of consortium meetings, and technical assistance with non-core management activities. These services are complementary to Biocat’s coordination role and are intended to enhance operational efficiency without outsourcing any core project responsibilities.

**ART-ER**

**Cost foreseen: 24.000 € (out of 40.000 €)**

ART-ER plans to subcontract the ad-hoc support of a Health Data Expert. The external consultant will provide specialised input for technical work related to health data, in line with ART-ER’s role in relevant work packages. This expertise is not available in-house and the subcontracting arrangement is specific and time-limited.

**RER**

**Cost foreseen: 5.000 € (out of 35.000 €)**

RER intends to reallocate part of its budget from “Other goods, works, and services” to subcontracting to engage an external expert in health data. In parallel, a shift from organising five smaller workshops to one major event is foreseen, aiming to increase operational efficiency and visibility. The subcontracting will support content development or technical facilitation but not cover core responsibilities.

**Biovia**

**Cost foreseen: 20.000 € (out of 100.000 €)**

Biovia will subcontract IT development and design services for the PRECISEU platform. This includes tasks such as UI/UX design and backend architecture. The subcontracting is justified by the need for specialised technical profiles and ensures timely and professional delivery of a key project output.

**SSP**

**Cost foreseen: 10.000 € (out of 40.000 €)**

SSP foresees subcontracting services for the event organisation of its yearly Hackathon. The subcontractor will manage logistics and production aspects, while SSP retains full responsibility for the programme, stakeholder engagement, and alignment with project objectives.

Does the participant envisage that part of its work is performed by affiliated entities (article 8 of MGA)?	N
<i>If yes, describe the affiliated entity, the link of the participant to the affiliated entity, and describe and justify the foreseen tasks to be performed by the affiliated entity.</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (articles 6.1 and 9.2 of MGA)?	N

<i>If yes, describe the third party and their contributions.</i>	
Does the participant envisage the provision of financial support to third parties (articles 6.2 D.1 and 9.4 of MGA)?	Y
<p><b>Biocat</b>  <b>Cost foreseen: 100.000 €</b></p> <p>Biocat envisages providing financial support to third parties within the framework of the Joint Interregional Projects (JIPs). Following the signature of the Grant Agreements for the selected projects, expected in February 2026, Biocat will issue a <b>pre-financing payment of 50%</b> of the granted contribution. Payments will be made within the timelines established by the corresponding funding agency, and in any case within <b>30 days</b> from the agreement's entry into force.</p> <p><b>SALUT</b>  <b>Cost foreseen: 2.000.000 €</b></p> <p>SALUT anticipates providing financial support to third parties in the context of funding regional stakeholders through the JIPs mechanism. Details regarding the disbursement structure will align with the general funding conditions and will be coordinated to ensure timely support to awarded consortia, in compliance with the FSTP framework.</p> <p><b>BIOPRO</b>  <b>Cost foreseen: 800.000 €</b></p> <p>BIOPRO plans to manage 50% of the total <b>1.6 million €</b> foreseen for financial support to third parties under its responsibility. This amount corresponds to the EU contribution. The financial support will be granted to selected regional innovation actors participating in the Joint Interregional Projects, following the approval and formalisation of individual agreements.</p> <p><b>NE</b> <span style="float: right;"><b>RDA</b></span>  <b>Cost foreseen: 500.000 €</b></p> <p>NE RDA will provide financial support to third parties, with <b>pre-financing disbursements foreseen after Grant Agreement signatures</b> in February 2026. A percentage of the granted amount will be transferred to the selected entities within <b>30 days</b>, according to internal procedures and legal obligations of the managing agency.</p> <p><b>DIZNE</b>  <b>Cost foreseen: 35.000 €</b></p>	

DIZNE plans to allocate financial support to selected regional innovation actors as part of the project's cascade funding activities. The amount will be disbursed based on contractual milestones and aligned with project-level funding decisions.

#### **SIA**

**Cost foreseen: not specified**

SIA has not specified an amount at this stage but may consider the provision of financial support to third parties at a later phase, subject to internal strategic and financial planning. Project continuity is currently under discussion.

#### **RER**

**Cost foreseen: 0 €**

RER does not envisage the provision of financial support to third parties. No pre-financing mechanism is planned by the Emilia-Romagna Region under the current implementation framework.

#### **IA**

**Lithuania**

**Cost foreseen: 60.000 €**

IA Lithuania will provide financial support to third parties under the Joint Interregional Projects (JIPs) scheme. In accordance with the national regulatory framework — *Rules for Administration and Financing of Projects under the 2021–2027 EU Funds Investment Programme and the Recovery and Resilience Facility “NextGeneration Lithuania”* — the **maximum advance payment may not exceed 30%** of the total project funding allocated for implementation. Accordingly, the total financial support to third parties under IA Lithuania's responsibility is capped at **60.000 €**, to be disbursed following Grant Agreement signature, expected in February 2026, and within a maximum of 30 days.

#### **ACCIO**

**Cost foreseen: 300.000 €**

ACCIO plans to provide financial support to regional stakeholders selected through the PRECISEU open call. The support will follow a pre-financing model and comply with national and EU-level co-funding rules, ensuring smooth and timely financial flow.

#### **Perifereia**

**Cost foreseen: 300.000 €**

The Region of Crete intends to allocate financial support to third parties, targeting innovation actors in the local ecosystem. The funds will be distributed under the FSTP framework to foster participation in joint interregional initiatives aligned with personalised medicine.

Does the participant envisage that part of the work is performed by associated partners <sup>6</sup> (Article 9.1 of the MGA)?	N
<i>If yes, please describe the associated partner(s) and their contributions.</i>	

### 3.5 RESOURCES TO BE COMMITTED

**Table 2.3.d: Summary of staff effort**

Number of person/months over the whole duration of the programmed activities, for set of activities, for each participant. Identify the activity leader for each set of activities by showing the relevant person-month figure in bold.

	WP1	WP2	Wp3	WP4	WP5	WP6	WP7	WP8	WP9	Total PM / Partner
Biocat	12	5	3,31	0,2	0,2	0,2	3	0,4	5,4	29,71
SALUT	0,36	0,2	0,66	0,2	1	1,4	1	10,8	1	16,62
BSC CNS	0,1	0,1	0,93	8	0	0	0	0,4	0,1	9,63
BIORN	0,1	0,4	1,76	0,1	8,2	0,8	3	2	1	17,36
BIOPRO	0,36	0,6	0,44	3,2	7,7	3,2	1,8	0,2	2,5	20
NE RDA	0,36	6,4	0,57	0	0	0,6	0,9	1	0,6	10,43
DIZNE	0,1	0,4	0,1	0	0	0,2	1,8	0	0,8	3,4
IMAGO-MOL	0,1	0,6	0,1	0	0	0,6	0,9	0,2	0	2,5
HLSCB	0,36	0,4	0,25	0	0	0,6	7,8	0	0,6	10,01
SIA	0,1	0,1	0	0	0	0	0	0,3	0,3	0,8
CLUST-ER	0,1	0,4	1,14	1	1,2	1	0,6	0	0,2	5,64
RER	0,1	0,1	0	0,3	0,2	0,3	0	0,3	3,2	4,5
ART-ER	0,36	0,4	0,46	4,4	0,4	0,4	0,2	0,2	0,2	7,02
EWI	0,1	0,4	1,76	0	0,4	0,4	0,2	0,2	0,2	3,66
Biovia	0,2	2,8	6,83	1	6,4	4	1	2	4,2	28,43

<sup>6</sup> Entities which participate in the action, but without the right to charge costs or claim contributions.

IA Lithuania	0,36	0,4	17	0,2	0,2	1	1	1	0,8	21,96
BRG	0,1	2	2,28	0,2	3,4	0,06	0	0	0	8,04
EATRIS	0,2	0,3	2,79	1,8	5,6	1,8	0,2	0	0	12,69
POP	0,1	1	4,57	0,2	3,4	3,2	3,2	0,1	0	15,77
ACCIO	0,2	0,8	1,24	0	0	1,6	0,4	0	5,2	9,44
FORTH-ICS	0,1	0,2	3,72	4,6	3	3,6	0	2,5	0,2	17,92
KRITI	0,1	0,2	0,31	0	0	0	0	0,2	0,8	1,61
SSP	0,36	3,5	0,46	0,2	2,34	10,6	1	2,2	0,6	21,26
RIMC	0,08	0,1	0,1	0,04	0	0,08	0,06	0,1	0	0,56
ASTRAZENECA	0,1	0,4	2,86	0,2	0	3,6	1,5	0,2	6,1	14,96
<b>Total PM</b>	<b>16,5</b>	<b>27,2</b>	<b>53,64</b>	<b>25,84</b>	<b>43,64</b>	<b>39,24</b>	<b>29,56</b>	<b>24,3</b>	<b>34</b>	<b>293,92</b>

The total amount of Person Months is consistent with the distribution per programmed activities and basal activities of the partners.

**Table 2.3.e: 'Purchase costs' items (travel and subsistence, equipment and other goods, works and services)**

1. Biocat		
	Cost (€)	Justification
Travel and subsistence	6.000	Travel to GAM#3 and other PRECISEU workshops and EU presidencies events.
Other goods, works and services	17.000	Networking and joint activities with other initiatives.
<b>Total</b>	<b>23.000</b>	

2. SALUT		
	Cost (€)	Justification
Travel and subsistence	6.000	Travel to GAM#3 and other PRECISEU workshops and activities.

3. BSC CNS		
	Cost (€)	Justification
Travel and subsistence	5.000	Travel to GAM#3 and other PRECISEU workshops and activities.

4. BIORN		
	Cost (€)	Justification
Travel and subsistence	6.000	Travel to GAM#3 and other PRECISEU workshops and activities.

5. BIOPRO		
	Cost (€)	Justification
Travel and subsistence	14,000€	A budget of 6,500€ has been allocated to enable the attendance of team members to project meetings: 2 <sup>nd</sup> Gam in September 2025 in Lithuania and visit 1 summer school in summer 2026.  Other 7,500€ has been reserved as travel costs for the invitation of external experts to the 5 workshops organized by WP5.
Other goods, works and services	14,000€	A budget of 14,000€ has been reserved for the organization of various thematic workshop for WP5.
<b>Total</b>	<b>28,000€</b>	

6. NE RDA		
	Cost (€)	Justification
Travel and subsistence	6,000	Travel to GAM#2 Vilnius GAM #3 Sofia, PRECISEU dissemination events

7. DIZNE		
	Cost (€)	Justification
Travel and subsistence	4,000	Travel to project meetings, Summer Schools and GAMs.

8. IMAGO-MOL		
	Cost (€)	Justification
Travel and subsistence	4,000	Travel to project meetings, Summer Schools and GAMs.

9. HLSCB		
	Cost (€)	Justification
Travel and subsistence	6.000	Travel to GAM#3 and attendance to Summer Schools and other PRECISEU project activities.
Other goods, works and services	37.000	Organization of GAM in Sofia, Bulgaria in the framework of the Spin Off Conference in June 2026. Invoices of the PM Summer Schools organized in the framework of WP in Iasi and Goteborg.
<b>Total</b>	<b>43.000</b>	

11. CLUST-ER		
	Cost (€)	Justification
Travel and subsistence	5.000	Allocated to enable the attendance of team members to project meetings, thematic workshop or networking events.

12. RER		
	Cost (€)	Justification
Travel and subsistence	3.000	Allocated to enable the attendance of team members to project meetings and General Assembly, thematic workshops or networking events.
Other goods, works and services	22.000	Organization of 1 workshop

13. ART-ER		
	Cost (€)	Justification
Travel and subsistence	3.000	Allocated to enable the attendance of team members to project meetings and General Assembly, thematic workshop or networking events.

14. EWI		
	Cost (€)	Justification
Travel and subsistence	4.000	Attendance to GAM and other PRECISEU-related events.

15. Biovia		
	Cost (€)	Justification
Travel and subsistence	12.000	To cover expenses of experts attending project meetings as well as supporting the traveling of team members to the PRECISEU GAM, and other project-related activities.

16. IA Lithuania		
	Cost (€)	Justification
Travel and subsistence	6.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events.
Other goods, works and services	40.000	A budget of 40.000€ has been reserved for the organization of GAM (M15).
<b>Total</b>	<b>46.000</b>	

17. BRG		
	Cost (€)	Justification

<b>Travel and subsistence</b>	6.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events.
-------------------------------	-------	--

18. EATRIS		
	Cost (€)	Justification
<b>Travel and subsistence</b>	6.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events.

19. POP		
	Cost (€)	Justification
<b>Travel and subsistence</b>	6.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events.

20. ACCIO		
	Cost (€)	Justification
<b>Travel and subsistence</b>	6.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events.

21. FORTH-ICS		
	Cost (€)	Justification
<b>Travel and subsistence</b>	6.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events.

22. Perifereia		
	Cost (€)	Justification
<b>Travel and subsistence</b>	8.000	Allocated to enable the attendance of team members to project meetings, thematic workshops or networking events.
<b>Other goods, works and services</b>	6.000	To provide the cost of the consultancy services

23. SSP		
	Cost (€)	Justification
<b>Travel and subsistence</b>	12.000	Allocated to enable the attendance of team members to project meetings, Summer School, thematic workshop or networking events. To cover the expenses of external experts invited to WP6 workshops.

<b>Other goods, works and services</b>	12.000	To cover the organization of one hackathon and one WP6 Thematic workshop.
<b>Total</b>	24.000	

<b>24. RIMC</b>		
	<b>Cost (€)</b>	<b>Justification</b>
<b>Travel and subsistence</b>	4.000	Allocated to enable the attendance of team members to project meetings, thematic Workshops or networking events.

<b>25. ASTRAZENECA</b>		
	<b>Cost (€)</b>	<b>Justification</b>
<b>Travel and subsistence</b>	6.000	Allocated to enable the attendance of team members to project meetings, thematic workshops, Summer Schools, or networking events.